BG63190B1 - Използване на оптически чист (+) норцисаприд за лечение на емезис и смущения на централната нервна система - Google Patents

Използване на оптически чист (+) норцисаприд за лечение на емезис и смущения на централната нервна система Download PDF

Info

Publication number
BG63190B1
BG63190B1 BG102757A BG10275798A BG63190B1 BG 63190 B1 BG63190 B1 BG 63190B1 BG 102757 A BG102757 A BG 102757A BG 10275798 A BG10275798 A BG 10275798A BG 63190 B1 BG63190 B1 BG 63190B1
Authority
BG
Bulgaria
Prior art keywords
norcisapride
pharmaceutically acceptable
acceptable salt
composition according
cisapride
Prior art date
Application number
BG102757A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102757A (en
Inventor
John Mccullough
Thomas JERUSSI
Original Assignee
Sepracor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc. filed Critical Sepracor Inc.
Publication of BG102757A publication Critical patent/BG102757A/xx
Publication of BG63190B1 publication Critical patent/BG63190B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG102757A 1996-07-19 1998-09-09 Използване на оптически чист (+) норцисаприд за лечение на емезис и смущения на централната нервна система BG63190B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/684,753 US5739151A (en) 1996-07-19 1996-07-19 Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
PCT/US1997/011629 WO1998003173A1 (en) 1996-07-19 1997-07-02 Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Publications (2)

Publication Number Publication Date
BG102757A BG102757A (en) 1999-08-31
BG63190B1 true BG63190B1 (bg) 2001-06-29

Family

ID=24749413

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102757A BG63190B1 (bg) 1996-07-19 1998-09-09 Използване на оптически чист (+) норцисаприд за лечение на емезис и смущения на централната нервна система

Country Status (25)

Country Link
US (3) US5739151A (xx)
EP (1) EP0896539B1 (xx)
JP (1) JP3097697B2 (xx)
KR (4) KR100533237B1 (xx)
CN (1) CN1215992A (xx)
AT (1) ATE197762T1 (xx)
AU (1) AU3592097A (xx)
BG (1) BG63190B1 (xx)
BR (1) BR9708287A (xx)
CA (1) CA2245768C (xx)
CZ (1) CZ293478B6 (xx)
DE (1) DE69703617T2 (xx)
DK (1) DK0896539T3 (xx)
ES (1) ES2152687T3 (xx)
GR (1) GR3035460T3 (xx)
HU (1) HUP9904360A3 (xx)
IL (1) IL125703A0 (xx)
IS (1) IS4820A (xx)
NO (2) NO317178B1 (xx)
NZ (1) NZ331291A (xx)
PL (1) PL189610B1 (xx)
PT (1) PT896539E (xx)
SK (1) SK282673B6 (xx)
TR (1) TR199801816T2 (xx)
WO (1) WO1998003173A1 (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
AU5050098A (en) * 1996-10-15 1998-05-11 Janssen Pharmaceutica N.V. Synthesis of cisapride
CZ296212B6 (cs) * 1997-07-11 2006-02-15 Janssen Pharmaceutica N. V. Lécivo pro lécení gastrointestinálního traktu
EP1468685A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
EP1464333A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
ES2237117T3 (es) * 1998-06-15 2005-07-16 Sepracor Inc. Uso de (-)norcisaprida opticamente pura en el tratamiento del sindrome del intestino irritable.
TR200003708T2 (tr) 1998-06-15 2001-06-21 Sepracor Inc. Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı.
CA2338794C (en) * 1998-08-21 2009-01-20 Novartis Ag New oral formulation for 5-ht4 agonists or antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6803387B1 (en) * 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
FR2854072B1 (fr) * 2003-04-23 2006-08-04 Centre Nat Rech Scient Vecteur pour administration par voie orale
RU2374244C2 (ru) * 2004-01-07 2009-11-27 Арикс Терапьютикс Стереоизомерные соединения и способы лечения желудочно-кишечных расстройств и расстройств центральной нервной системы
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US20090170899A1 (en) * 2004-09-14 2009-07-02 Guy Debonnel Stimulators of 5-HT4 receptors and uses thereof
JP5308818B2 (ja) * 2005-08-31 2013-10-09 アルメテオン、インコーポレイテッド 胃腸系および中枢神経系障害の治療に有用な立体異性化合物の合成方法および中間体
US20080085915A1 (en) * 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
CN102655860B (zh) 2009-10-16 2013-11-06 艾皮奥梅医药公司 呕吐的治疗
EP2678331B1 (en) * 2011-02-25 2016-04-27 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5114715A (en) * 1990-11-29 1992-05-19 Sepracor Inc. Methods of use and compositions of (s)-isoflurane and (s)-desflurane
US5114714A (en) * 1990-11-29 1992-05-19 Sepracor, Inc. Methods of use and compositions of (r)-isoflurane and (r)-desflurane
AU4770593A (en) * 1992-07-07 1994-01-31 Sepracor, Inc. Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
AU4666393A (en) * 1992-07-07 1994-01-31 Sepracor, Inc. Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
JPH08512322A (ja) * 1993-07-06 1996-12-24 メルク エンド カンパニー インコーポレーテッド Ｈ▲下２▼拮抗剤−胃腸運動性の薬剤組合せ物
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Also Published As

Publication number Publication date
KR100422492B1 (ko) 2004-03-11
NO317178B1 (no) 2004-09-06
EP0896539B1 (en) 2000-11-29
US5739151A (en) 1998-04-14
IL125703A0 (en) 1999-04-11
DE69703617D1 (de) 2001-01-04
KR100533237B1 (ko) 2005-12-05
BR9708287A (pt) 2000-01-18
KR100328731B1 (ko) 2002-10-19
NO983636L (no) 1998-10-19
DE69703617T2 (de) 2001-04-12
CZ250898A3 (cs) 1999-04-14
SK282673B6 (sk) 2002-11-06
EP0896539A1 (en) 1999-02-17
TR199801816T2 (xx) 2000-10-23
NO983636D0 (no) 1998-08-07
KR100399808B1 (ko) 2003-09-29
CN1215992A (zh) 1999-05-05
NZ331291A (en) 2000-06-23
US5877188A (en) 1999-03-02
PL335254A1 (en) 2000-04-10
BG102757A (en) 1999-08-31
HUP9904360A3 (en) 2001-07-30
PL189610B1 (pl) 2005-08-31
ATE197762T1 (de) 2000-12-15
IS4820A (is) 1998-08-10
WO1998003173A1 (en) 1998-01-29
HUP9904360A2 (hu) 2000-05-28
JPH11510828A (ja) 1999-09-21
ES2152687T3 (es) 2001-02-01
KR20000064524A (ko) 2000-11-06
NO20041166L (no) 2004-03-19
JP3097697B2 (ja) 2000-10-10
GR3035460T3 (en) 2001-05-31
CZ293478B6 (cs) 2004-05-12
AU3592097A (en) 1998-02-10
US6114356A (en) 2000-09-05
KR20040007505A (ko) 2004-01-24
PT896539E (pt) 2001-05-31
SK123998A3 (en) 1999-03-12
CA2245768C (en) 2003-09-30
DK0896539T3 (da) 2001-02-19
CA2245768A1 (en) 1998-01-29

Similar Documents

Publication Publication Date Title
EP0896539B1 (en) Use of optically pure (+) norcisapride for treating emesis and central nervous system disorders
EP0831821B1 (en) Optically pure (-) norcisapride for treating digestive tract disorders
US6632827B2 (en) Compositions of optically pure (+) norcisapride
AU780107B2 (en) Methods for treating emesis and central nervous system disorders using optically pure () norcisapride
MXPA01000919A (en) Methods and compositions for treating gastro-esophageal reflux disease